Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Indian Heart J ; 66(2): 164-8, 2014.
Article in English | MEDLINE | ID: mdl-24814109

ABSTRACT

BACKGROUND: Patients with mitral restenosis who have undergone prior PTMC or surgical commissurotomy have increased. Predictors of outcome of repeat PTMC in either subgroup of patients may be different. AIMS AND OBJECTIVES: Aim was to assess and compare the immediate results of PTMC in patients who had undergone a prior PTMC or surgical commissurotomy. METHODS AND RESULTS: This is a single center, prospective, open label study. Of 70 patients in study, 44 (62.85%) patients had prior history of PTMC and 26 (37.15%) had prior surgical commissurotomy (closed/open). Average time from the initial procedure was 8.88 ± 5.36 years overall, 6.75 ± 3.38 for patients with prior PTMC and 16.73 ± 3.67 for patients with prior surgical commissurotomy. Prior PTMC group had 75% female, patients with prior surgical commissurotomy were older (44 ± 7 vs 33.57 ± 9.1 years, p = 0.001), had higher NYHA class (III/IV in100% vs 86.36%, p = 0.006.), higher atrial fibrillation (73.1% vs 25% p < 0.0001) and higher Wilkins' score (>8 in 88.46% vs 68.18%, p = 0.05). Successful PTMC was lower (65.4% vs 84.1%) in patients with prior surgical commissurotomy, though statistically not significant (p = 0.07). After PTMC, mitral valve area, PA systolic pressure, LA mean pressure and trans-mitral gradient were similar. Post procedure complications were not different in both the groups. CONCLUSION: PTMC for mitral restenosis in patients with prior surgical valvotomy is as effective as in patients with prior PTMC despite older age, higher NYHA class, higher Wilkins score and atrial fibrillation and can be considered in all patients with restenosis irrespective of the type of past procedures done.


Subject(s)
Cardiac Catheterization/methods , Mitral Valve Annuloplasty/adverse effects , Mitral Valve Stenosis/mortality , Mitral Valve Stenosis/surgery , Adult , Cohort Studies , Echocardiography, Transesophageal/methods , Female , Follow-Up Studies , Humans , India , Male , Middle Aged , Minimally Invasive Surgical Procedures/adverse effects , Minimally Invasive Surgical Procedures/methods , Mitral Valve Annuloplasty/methods , Mitral Valve Stenosis/diagnostic imaging , Prospective Studies , Recurrence , Reoperation/methods , Reoperation/mortality , Risk Assessment , Survival Rate , Treatment Outcome
3.
J Thromb Thrombolysis ; 38(1): 24-9, 2014 Jul.
Article in English | MEDLINE | ID: mdl-23975441

ABSTRACT

Pulmonary embolism (PE) is a relatively common life-threatening cardiovascular condition associated with significant morbidity and mortality. We present the efficacy and safety data of weight-adjusted tenecteplase in 30 consecutive patients of acute PE. 30 patients (22 male, 8 female) with acute PE were included in the study and divided into three groups: (1) Acute PE complicated by shock stage and/or persistent hypotension (12 patients). (2) RV dilatation and/or dysfunction without hypotension (14 patients). (3) Severe hypoxemia without hypotension and RV dysfunction (4 patients). Predominant symptoms were dyspnoea, cough, chest pain, syncope and haemoptysis, noted in 100% (30), 40% (12), 54% (16), 32% (9) and 10% (3) of patients respectively. RV dilatation and dyskinesia were present in 86%, septal paradoxical movement in 73% and inferior venacava collapse absent in 53% of patients respectively. 12 patients presented with acute PE and cardiogenic shock, 14 patients showed RV dilatation and dysfunction with systolic BP >90 mmHg and four patients were having RV dilation without dysfunction but severe hypoxemia. There was significant reduction in right ventricular systolic pressure and improvement in right ventricular dysfunction. Our study shows that tenecteplase is very effective and safe in the treatment of PE with minimal risk of bleeding in high risk group and intermediate risk and even in selective low risk category group of patients. However, in view of small number of patients in study group, a large multicentre randomized study would be required to draw a firm conclusion regarding the thrombolysis in low risk category patient.


Subject(s)
Fibrinolytic Agents/administration & dosage , Pulmonary Embolism/drug therapy , Tissue Plasminogen Activator/administration & dosage , Adult , Female , Fibrinolytic Agents/adverse effects , Hemorrhage/chemically induced , Hemorrhage/physiopathology , Humans , Hypotension/complications , Hypotension/drug therapy , Hypotension/physiopathology , Hypoxia/complications , Hypoxia/drug therapy , Hypoxia/physiopathology , Male , Middle Aged , Pulmonary Embolism/complications , Pulmonary Embolism/physiopathology , Risk Factors , Shock, Cardiogenic/complications , Shock, Cardiogenic/drug therapy , Shock, Cardiogenic/physiopathology , Tenecteplase , Tissue Plasminogen Activator/adverse effects , Ventricular Dysfunction, Right/complications , Ventricular Dysfunction, Right/drug therapy , Ventricular Dysfunction, Right/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...